FeesSafety
Pluang+

Pharming Group posts 21% revenue growth in Q3 2026, beating expectations with strong drug sales.

Company Fundamentals
22 Oct 2026
GlobeNewsWire
View Source
Bullish
Pharming Group posts 21% revenue growth in Q3 2026, beating expectations with strong drug sales.

Pharming Group reported a 21% increase in total revenues for Q3 2026, reaching approximately $117.6 million, driven by strong sales of RUCONEST and Joenja. Operating expenses remained stable at about $74.6 million, reflecting efficient business scaling. The company tightened its 2026 revenue guidance to $380-$390 million and lowered operating expense forecasts. Upcoming clinical trial results and a full financial report are expected on October 27, 2026, signaling continued growth potential in rare disease treatments.

Pharming Group's Q3 2026 revenue announcement provides context for healthcare sector activity on Pluang. As of Oct 22, 2026 12:11 WIB, out of 150 priced Health-sector US stocks, 70 rose and 79 fell. Notable movers include CTXR at USD 0.40 with a 1-day change of -5.25%, CRON at USD 3.45 up 5.18%, and MRVI at USD 7.57 up 5.14%.

More News

Nexans chosen as preferred supplier for Mallorca-Menorca power cable project to boost Balearic Islands' grid resilience.

Nexans chosen as preferred supplier for Mallorca-Menorca power cable project to boost Balearic Islands' grid resilience.

Nexans has been selected by Red Eléctrica as the preferred supplier for the Mallorca-Menorca 3 interconnection project, a key infrastructure initiative aimed at strengthening the electricity network's security and resilience in the Balearic Islands. ...

Market News
Bullish
23 minutes ago
Roche posts 7% sales growth in Q3 2026, driven by strong demand for innovative medicines and diagnostics.

Roche posts 7% sales growth in Q3 2026, driven by strong demand for innovative medicines and diagnostics.

Roche reported a 7% sales increase at constant exchange rates in Q3 2026, with a 6% rise for the first nine months, fueled by high demand for key medicines like Xolair, Hemlibra, and Ocrevus. The Pharmaceuticals Division led growth, while Diagnostics...

Company Fundamentals
Bullish
23 minutes ago
Ipsen raises 2026 sales growth forecast to 23% after strong Q3 performance

Ipsen raises 2026 sales growth forecast to 23% after strong Q3 performance

Ipsen reported a 24.6% sales growth at constant exchange rates for the first nine months of 2026, driven by strong performance in Oncology, Rare Disease, and Neuroscience segments. The company upgraded its full-year sales growth guidance to around 23...

Company Fundamentals
Bullish
23 minutes ago
Nexans chosen as preferred supplier for Mallorca-Menorca power interconnection project with Red Eléctrica.

Nexans chosen as preferred supplier for Mallorca-Menorca power interconnection project with Red Eléctrica.

Nexans has been selected by Red Eléctrica as the preferred supplier for the Mallorca-Menorca 3 interconnection project, aimed at enhancing the electricity network's security and resilience in the Balearic Islands. The project includes a six-month eng...

Market News
Bullish
23 minutes ago
Nexans reports 10.1% revenue growth in 9M 2026, confirms 2026 outlook with strong performance in electrification segments.

Nexans reports 10.1% revenue growth in 9M 2026, confirms 2026 outlook with strong performance in electrification segments.

Nexans posted a 10.1% increase in revenue to €4.95 billion for the first nine months of 2026, driven by strong organic growth in its electrification segments PWR-Grid and PWR-Connect. The company successfully integrated Republic Wire in the US and co...

Company Fundamentals
Bullish
23 minutes ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App